Short seller Scorpion Capital has publicly questioned the validity of Twist Biosciences' claims regarding its AI partnerships. The firm disclosed a short position in the company, citing concerns over the accuracy of reported collaborations.
Twist Biosciences has not yet responded to requests for comment on the allegations. Further verified details regarding the partnerships or the short seller's evidence were not immediately available.
